{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:24:59Z","timestamp":1781537099122,"version":"3.54.5"},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.phrs.2012.01.007","type":"journal-article","created":{"date-parts":[[2012,1,29]],"date-time":"2012-01-29T16:27:46Z","timestamp":1327854466000},"page":"402-410","source":"Crossref","is-referenced-by-count":7,"title":["Novel LDL-oriented pharmacotherapeutical strategies"],"prefix":"10.1016","volume":"65","author":[{"given":"Lin-Zhang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2012.01.007_bib0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1517\/13543776.2011.547478","article-title":"Novel 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors: a patent review","volume":"21","author":"Pfefferkorn","year":"2011","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.phrs.2012.01.007_bib0010","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1161\/hc4601.099487","article-title":"Global burden of cardiovascular diseases. Part I. General considerations, the epidemiologic transition, risk factors, and impact of urbanization","volume":"104","author":"Yusuf","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2012.01.007_bib0015","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","article-title":"Heart disease and stroke statistics\u20142011 update: a report from the american heart association","volume":"123","author":"Roger","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2012.01.007_bib0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1517\/14728214.2011.554395","article-title":"Emerging options in the treatment of dyslipidemias: a bright future?","volume":"16","author":"Florentin","year":"2011","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.phrs.2012.01.007_bib0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/14740338.2011.540237","article-title":"Safety review of combination drugs for hyperlipidemia","volume":"10","author":"Farnier","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.phrs.2012.01.007_bib0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrcardio.2011.2","article-title":"Pharmacological strategies for lowering LDL cholesterol: statins and beyond","volume":"8","author":"Brautbar","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0035","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1008-1050","article-title":"A gift from nature: the birth of the statins","volume":"14","author":"Endo","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.phrs.2012.01.007_bib0040","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/01.CIR.91.10.2528","article-title":"Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The regression growth evaluation statin study (REGRESS)","volume":"91","author":"Jukema","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2012.01.007_bib0045","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1517\/14656561003774080","article-title":"Advancing therapy for hypercholesterolemia","volume":"11","author":"Toutouzas","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.phrs.2012.01.007_bib0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11883-008-0008-0","article-title":"Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia?","volume":"10","author":"Mays","year":"2008","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.phrs.2012.01.007_bib0055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2006.10.001","article-title":"Statin-associated adverse effects beyond muscle and liver toxicity","volume":"195","author":"Kiortsis","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2012.01.007_bib0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MOL.0b013e32825a6773","article-title":"The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis","volume":"18","author":"Harper","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0065","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11886-003-0109-x","article-title":"Niacin, lipids, and heart disease","volume":"5","author":"Malik","year":"2003","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.phrs.2012.01.007_bib0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.0954-6820.1962.tb07203.x","article-title":"The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis","volume":"172","author":"Carlson","year":"1962","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.phrs.2012.01.007_bib0075","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1742-1241.2009.02099.x","article-title":"The mechanism and mitigation of niacin-induced flushing","volume":"63","author":"Kamanna","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.phrs.2012.01.007_bib0080","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2147\/VHRM.S4502","article-title":"Review of extended-release niacin\/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia","volume":"5","author":"Parhofer","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.phrs.2012.01.007_bib0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4137\/CMC.S7601","article-title":"Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters","volume":"5","author":"Vosper","year":"2011","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/14728214.2010.481282","article-title":"Emerging drugs for hyperlipidemia","volume":"15","author":"Paras","year":"2010","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.phrs.2012.01.007_bib0095","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjcard.2005.11.039","article-title":"Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity c-reactive protein when added to statins in patients with hypercholesterolemia","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2012.01.007_bib0100","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/BF03216291","article-title":"Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism","volume":"40","author":"Einarsson","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0105","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-pick c1 like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.phrs.2012.01.007_bib0110","doi-asserted-by":"crossref","first-page":"33586","DOI":"10.1074\/jbc.M405817200","article-title":"Niemann-pick c1 like 1 (npc1l1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis","volume":"279","author":"Davis","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2012.01.007_bib0115","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.phrs.2012.01.007_bib0120","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0002-9149(02)02798-4","article-title":"Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia","volume":"90","author":"Dujovne","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0125","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2012.01.007_bib0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0135","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0022-2275(20)38310-3","article-title":"Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review","volume":"30","author":"Harris","year":"1989","journal-title":"J Lipid Res"},{"key":"10.1016\/j.phrs.2012.01.007_bib0140","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0022-2275(20)38418-2","article-title":"Eicosapentaenoic acid reduces hepatic synthesis and secretion of triacylglycerol by decreasing the activity of acyl-coenzyme a:1,2-diacylglycerol acyltransferase","volume":"29","author":"Rustan","year":"1988","journal-title":"J Lipid Res"},{"key":"10.1016\/j.phrs.2012.01.007_bib0145","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1753-4887.2004.tb00058.x","article-title":"Polyunsaturated fatty acid regulation of gene expression","volume":"62","author":"Sampath","year":"2004","journal-title":"Nutr Rev"},{"key":"10.1016\/j.phrs.2012.01.007_bib0150","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00043798-199710000-00011","article-title":"Safety and efficacy of omacor in severe hypertriglyceridemia","volume":"4","author":"Harris","year":"1997","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.phrs.2012.01.007_bib0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pharmthera.2010.02.006","article-title":"Molecular pathways and agents for lowering LDL-cholesterol in addition to statins","volume":"126","author":"Costet","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.phrs.2012.01.007_bib0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1399-0004.2008.01099.x","article-title":"Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway","volume":"75","author":"Do","year":"2009","journal-title":"Clin Genet"},{"key":"10.1016\/j.phrs.2012.01.007_bib0165","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.bjp.0705332","article-title":"Lipid-lowering properties of tak-475, a squalene synthase inhibitor, in vivo and in vitro","volume":"139","author":"Nishimoto","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0170","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1161\/CIRCULATIONAHA.110.975284","article-title":"Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia","volume":"123","author":"Stein","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2012.01.007_bib0175","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.bmcl.2011.02.004","article-title":"Identification and optimization of tetrahydro-2h-3-benzazepin-2-ones as squalene synthase inhibitors","volume":"21","author":"Griebenow","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.phrs.2012.01.007_bib0180","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10156-010-0190-1","article-title":"Two squalene synthase inhibitors, e5700 and er-119884, interfere with cellular proliferation and induce ultrastructural and lipid profile alterations in a candida tropicalis strain resistant to fluconazole, itraconazole, and amphotericin b","volume":"17","author":"Ishida","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.phrs.2012.01.007_bib0185","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1016\/j.bmcl.2011.04.092","article-title":"Identification of 4h,6h-[2]benzoxepino[4,5-c][1,2]oxazoles as novel squalene synthase inhibitors","volume":"21","author":"Griebenow","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.phrs.2012.01.007_bib0190","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1016\/j.bmc.2011.07.007","article-title":"Discovery of atrop fixed alkoxy-aminobenzhydrol derivatives: novel, highly potent and orally efficacious squalene synthase inhibitors","volume":"19","author":"Ichikawa","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.phrs.2012.01.007_bib0195","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.bmc.2011.01.065","article-title":"Discovery of a new 2-aminobenzhydrol template for highly potent squalene synthase inhibitors","volume":"19","author":"Ichikawa","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.phrs.2012.01.007_bib0200","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1388-1981(00)00144-X","article-title":"Mammalian acyl-CoA:cholesterol acyltransferases","volume":"1529","author":"Buhman","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.phrs.2012.01.007_bib0205","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev.biochem.66.1.613","article-title":"Acyl-coenzyme a:cholesterol acyltransferase","volume":"66","author":"Chang","year":"1997","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.phrs.2012.01.007_bib0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00129784-200808040-00003","article-title":"Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins","volume":"8","author":"El Harchaoui","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.phrs.2012.01.007_bib0215","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jama.301.11.1131","article-title":"Acat inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the captivate randomized trial","volume":"301","author":"Meuwese","year":"2009","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.phrs.2012.01.007_bib0220","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1248\/cpb.58.1057","article-title":"Novel acyl-CoA:cholesterol acyltransferase inhibitor: indoline-based sulfamide derivatives with low lipophilicity and protein binding ratio","volume":"58","author":"Takahashi","year":"2010","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.phrs.2012.01.007_bib0225","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1248\/cpb.58.1066","article-title":"Novel tetrahydroisoquinoline derivatives with inhibitory activities against acyl-CoA:cholesterol acyltransferase and lipid peroxidation","volume":"58","author":"Ohta","year":"2010","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.phrs.2012.01.007_bib0230","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1248\/cpb.59.1268","article-title":"Discovery of a potent and orally available acyl-CoA:cholesterol acyltransferase inhibitor as an anti-atherosclerotic agent: (4-phenylcoumarin) acetanilide derivatives","volume":"59","author":"Ogino","year":"2011","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.phrs.2012.01.007_bib0235","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2010.08.048","article-title":"A selective acat-1 inhibitor, k-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein e-knockout mice","volume":"213","author":"Yoshinaka","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2012.01.007_bib0240","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/ATVBAHA.111.223552","article-title":"Pyripyropene a, an acyl-coenzyme a:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia","volume":"31","author":"Ohshiro","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0245","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11883-010-0151-2","article-title":"Therapies targeting exogenous cholesterol uptake: new insights and controversies","volume":"13","author":"Davidson","year":"2011","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.phrs.2012.01.007_bib0250","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/geno.2000.6151","article-title":"Evidence for a niemann-pick c (npc) gene family: identification and characterization of npc1l1","volume":"65","author":"Davies","year":"2000","journal-title":"Genomics"},{"key":"10.1016\/j.phrs.2012.01.007_bib0255","doi-asserted-by":"crossref","first-page":"12710","DOI":"10.1074\/jbc.M409110200","article-title":"Inactivation of npc1l1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia","volume":"280","author":"Davies","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2012.01.007_bib0260","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.14.99","article-title":"Inhibition of niemann-pick c1 like 1 (npc1l1) to reduce intestinal cholesterol absorption and treat hyperlipidemia","volume":"14","author":"Davis","year":"2007","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.phrs.2012.01.007_bib0265","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1016\/j.bmcl.2010.09.138","article-title":"Spiroimidazolidinone npc1l1 inhibitors. Part 2. Structure\u2013activity studies and in vivo efficacy","volume":"20","author":"Howell","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.phrs.2012.01.007_bib0270","first-page":"10","article-title":"Discovery of a novel and potent cholesterol absorption inhibitor (cai) as promising orally active lipid lowering drug","author":"Kanou","year":"2009","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.phrs.2012.01.007_bib0275","doi-asserted-by":"crossref","first-page":"A567","DOI":"10.1016\/S0016-5085(09)62611-1","article-title":"Curcumin down-regulates niemann-pick c1-like 1 expression in intestinal epithelial cells","volume":"136","author":"Kumar","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2012.01.007_bib0280","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.febslet.2010.03.030","article-title":"Npc1l1 and cholesterol transport","volume":"584","author":"Betters","year":"2010","journal-title":"FEBS Lett"},{"key":"10.1016\/j.phrs.2012.01.007_bib0285","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cjca.2010.12.020","article-title":"New insights into how the intestine can regulate lipid homeostasis and impact vascular disease: frontiers for new pharmaceutical therapies to lower cardiovascular disease risk","volume":"27","author":"Warnakula","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0290","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.phrs.2012.01.007_bib0295","doi-asserted-by":"crossref","first-page":"G532","DOI":"10.1152\/ajpgi.00052.2009","article-title":"Modulation of ileal apical Na+-dependent bile acid transporter asbt by protein kinase c","volume":"297","author":"Sarwar","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0300","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00005176-200104000-00002","article-title":"Intestinal bile acid transport: biology, physiology, and pathophysiology","volume":"32","author":"Shneider","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.phrs.2012.01.007_bib0305","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0169-409X(02)00007-8","article-title":"Modeling of active transport systems","volume":"54","author":"Zhang","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.phrs.2012.01.007_bib0310","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986706776361003","article-title":"Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs","volume":"13","author":"Kramer","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.phrs.2012.01.007_bib0315","article-title":"Identification of novel nonsteroidal compounds as substrates or inhibitors of hasbt","author":"Kolhatkar","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.phrs.2012.01.007_bib0320","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1021\/jm00033a001","article-title":"Specific inhibitors of ileal bile acid transport","volume":"37","author":"Wess","year":"1994","journal-title":"J Med Chem"},{"key":"10.1016\/j.phrs.2012.01.007_bib0325","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1016\/j.bmcl.2003.08.004","article-title":"A novel class of apical sodium co-dependent bile acid transporter inhibitors: the 1,2-benzothiazepines","volume":"13","author":"Tollefson","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.phrs.2012.01.007_bib0330","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1021\/jm040215+","article-title":"Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1)","volume":"48","author":"Tremont","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.phrs.2012.01.007_bib0335","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0022-2275(20)39868-0","article-title":"Effects of 2164u90 on ileal bile acid absorption and serum cholesterol in rats and mice","volume":"36","author":"Lewis","year":"1995","journal-title":"J Lipid Res"},{"key":"10.1016\/j.phrs.2012.01.007_bib0340","series-title":"Role of the intestinal bile acid transporters in bile acid and drug disposition","author":"Dawson","year":"2011"},{"key":"10.1016\/j.phrs.2012.01.007_bib0345","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1126\/science.1439810","article-title":"Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia","volume":"258","author":"Wetterau","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.phrs.2012.01.007_bib0350","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/MOL.0b013e3282feea85","article-title":"Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism","volume":"19","author":"Hussain","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0355","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2012.01.007_bib0360","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.phrs.2012.01.007_bib0365","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/ncpcardio1251","article-title":"Microsomal triglyceride transfer protein inhibition: friend or foe?","volume":"5","author":"Joy","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.phrs.2012.01.007_bib0370","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1463-1326.2011.01387.x","article-title":"Jtt-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in zucker diabetic fatty rats","volume":"13","author":"Hata","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.phrs.2012.01.007_bib0375","first-page":"5","article-title":"Jtt-130, a microsomal triglyceride transfer protein (mtp) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs","author":"Aggarwal","year":"2005","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.phrs.2012.01.007_bib0380","first-page":"10","article-title":"Clinical investigations into the role of mtp in chylomicron formation using slx-4090, an enterocyte-specific inhibitor","author":"Tong","year":"2009","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.phrs.2012.01.007_bib0385","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1124\/jpet.110.177527","article-title":"A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, slx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile","volume":"337","author":"Kim","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2012.01.007_bib0390","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.bmcl.2007.01.018","article-title":"In vitro and in vivo profile of 5-[(4\u2032-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1h-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent mtp inhibitor for obesity","volume":"17","author":"Li","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.phrs.2012.01.007_bib0395","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1016\/j.bmcl.2011.05.099","article-title":"Discovery of microsomal triglyceride transfer protein (mtp) inhibitors with potential for decreased active metabolite load compared to dirlotapide","volume":"21","author":"Robinson","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.phrs.2012.01.007_bib0400","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.106.012401","article-title":"Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, isis 301012, targeting human apolipoprotein b-100","volume":"35","author":"Yu","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.phrs.2012.01.007_bib0405","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jacl.2010.03.055","article-title":"Mipomersen, a first-in-class apolipoprotein b synthesis inhibitor, lowers lipoprotein (a) in patients with homozygous familial hypercholesterolemia","volume":"4","author":"Cromwell","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0410","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein b and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein b","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2012.01.007_bib0415","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nrcardio.2011.88","article-title":"Therapy: antisense inhibitor of apo b has potent lipoprotein effects","volume":"8","author":"Mearns","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0420","first-page":"e250","article-title":"Pharmacology, target reduction, and drug accumulation after oral feeding of an lna antisense oligonucleotide directed against apo-b 100","volume":"30","author":"Hardee","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0425","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of african descent resulting from frequent nonsense mutations in pcsk9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.phrs.2012.01.007_bib0430","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MOL.0b013e3281338531","article-title":"Unravelling the functional significance of pcsk9","volume":"18","author":"Lambert","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0435","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2012.01.007_bib0440","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/BJ20070664","article-title":"Secreted pcsk9 promotes LDL receptor degradation independently of proteolytic activity","volume":"406","author":"Li","year":"2007","journal-title":"Biochem J"},{"key":"10.1016\/j.phrs.2012.01.007_bib0445","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted pcsk9 to reduce low density lipoprotein receptors in hepg2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2012.01.007_bib0450","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in pcsk9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.phrs.2012.01.007_bib0455","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in pcsk9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2012.01.007_bib0460","article-title":"A proprotein convertase subtilisin-like\/kexin type 9 (pcsk9)-binding antibody that structurally mimics the egf (a) domain of LDL-receptor reduces free circulating pcsk9 and LDL-cholesterol","author":"Ni","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.phrs.2012.01.007_bib0465","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/14728222.2011.547480","article-title":"Pcsk9: an emerging target for treatment of hypercholesterolemia","volume":"15","author":"Duff","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.phrs.2012.01.007_bib0470","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/14728220802600715","article-title":"Pcsk9 as a therapeutic target of dyslipidemia","volume":"13","author":"Seidah","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.phrs.2012.01.007_bib0475","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1210\/me.2002-0009","article-title":"Requirement for thyroid hormone receptor beta in t3 regulation of cholesterol metabolism in mice","volume":"16","author":"Gullberg","year":"2002","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0480","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1073\/pnas.78.4.2591","article-title":"Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo","volume":"78","author":"Thompson","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2012.01.007_bib0485","first-page":"217","article-title":"The significance of alterations in serum lipids in thyroid dysfunction. II. Alterations of the metabolism and turnover of 131-I-low-density lipoproteins in hypothyroidism and thyrotoxicosis","volume":"29","author":"Walton","year":"1965","journal-title":"Clin Sci"},{"key":"10.1016\/j.phrs.2012.01.007_bib0490","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/S0140-6736(09)61047-3","article-title":"Recent developments in hyperthyroidism","volume":"373","author":"Kharlip","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2012.01.007_bib0495","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/emboj\/17.2.455","article-title":"Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1","volume":"17","author":"Wikstrom","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.phrs.2012.01.007_bib0500","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1210\/en.139.12.4945","article-title":"Thyroid hormone action on liver, heart, and energy expenditure in thyroid hormone receptor beta-deficient mice","volume":"139","author":"Weiss","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2012.01.007_bib0505","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1210\/me.14.11.1739","article-title":"Thyroid hormone receptor beta-deficient mice show complete loss of the normal cholesterol 7alpha-hydroxylase (cyp7a) response to thyroid hormone but display enhanced resistance to dietary cholesterol","volume":"14","author":"Gullberg","year":"2000","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.phrs.2012.01.007_bib0510","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1073\/pnas.0705286104","article-title":"The thyroid hormone mimetic compound kb2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans","volume":"105","author":"Berkenstam","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2012.01.007_bib0515","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2012.01.007_bib0520","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1021\/jm9504969","article-title":"The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors","volume":"39","author":"Chan","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.phrs.2012.01.007_bib0525","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661812000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661812000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T05:31:40Z","timestamp":1640583100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661812000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S1043661812000084"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2012.01.007","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}